862822-06-8

Basic information

• Product Name: (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester
• Synonyms: (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester
• CAS NO: 862822-06-8
• Molecular Formula: C₁₂H₁₃N₃O₄S
• Molecular Weight: 295.31432
• EINECS: -0
• Mol File: 862822-06-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester(862822-06-8)
• EPA Substance Registry System: (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester(862822-06-8)

Safety Data

• Hazardous Substances Data: 862822-06-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester is used as a building block for the synthesis of various pharmaceutical compounds. The presence of the carbamate and benzothiazole moieties makes it a versatile candidate for the development of new drugs with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of chemical synthesis, (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester is used as an intermediate for the preparation of other complex organic molecules. The electron-withdrawing nitro group and the protective tert-butyl ester group facilitate various synthetic transformations, making it a valuable component in the synthesis of target molecules.
Used in Material Science:
(6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester can be utilized in the development of novel materials with specific properties. The electron-withdrawing nature of the nitro group and the structural features of the benzothiazole ring may contribute to the creation of materials with unique electronic, optical, or mechanical properties.
Used in Research and Development:
(6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester serves as a valuable research tool for studying the properties and reactivity of carbamate derivatives and benzothiazole derivatives. It can be used in academic and industrial research to explore new reaction pathways, develop innovative synthetic methods, and investigate the structure-activity relationships of related molecules.

Upstream product

• 6285-57-0 2-amino-6-nitrobenzothiazole 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 862821-93-0 [6-(2,6-dichloro-benzoylamino)-benzothiazol-2-yl]-carbamic acid tert-butyl ester 
• 862822-08-0 N-(2-amino-benzothiazol-6-yl)-2,6-dichloro-benzamide 
• 862822-07-9 (6-aminobenzothiazol-2-yl)carbamic acid tert-butyl ester 

Relevant articles and documents

Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects

Inhibition of the soluble epoxide hydrolase (sEH) is a promising new therapeutic approach in the treatment of inflammation. Driven by the in-house database product lead 1, a hybridization strategy was utilized for the design of a series of novel benzo [d]thiazol derivatives. To our delight, D016, a byproduct of compound 9, was obtained with an extraordinarily low IC50 value of 0.1 nM but poor physical and chemical properties. After removal of a non-essential urea moiety or replacement of the urea group by an amide group, compounds 15a, 17p, and 18d were identified as promising sEH inhibitors, and their molecular binding modes to sEH were constructed. Furthermore, compounds 15a and 18d exhibited more effective in vivo anti-inflammatory effect than t-AUCB in carrageenan-induced mouse paw edema. Compound 15a also showed moderate metabolic stability with a half-time of 34.7 min. Although 18d was unstable in rat liver microsomes, it might be a “prodrug”. In conclusion, this study could provide valuable insights into discovery of new sEH inhibitors, and compounds 15a and 18d were worthy of further development as potential drug candidates to treat inflammation.

Benzothiazole derivatives and their uses

The present invention relates to benzothiazole derivatives and their uses, specifically to compounds shown in formula I or stereoisomers thereof and pharmaceutically acceptable salts, solvates or prodrugs thereof, methods of preparation thereof, and pharmaceutical compositions containing the compounds, wherein the substituentsR1,R2,R8 , X, Y, Z, Q have the meaning given in the instruction manual. The present invention further relates to the application of compounds of formula I in the preparation of drugs for the treatment and / or prevention of sEH-mediated diseases, in particular in the preparation of drugs for the treatment of inflammatory diseases, cardiovascular and cerebrovascular diseases, diabetes mellitus, diabetic complications, diabetes-related diseases, fibrotic diseases, neurological and psychiatric diseases, pain, ulcerative diseases and the like.

Selective sodium channel regulator as well as preparation and application thereof

The invention provides a compound serving as a selective sodium channel regulator and a synthesis and use method, and particularly provides a compound shown as a formula (I), a preparation method of the compound and application of the compound serving as the selective sodium channel regulator. The compounds exhibit excellent activity as a regulator of sodium channels.

Benzothiazole compounds and medical application

The invention discloses a benzothiazole compound and medical application thereof, particularly relates to a benzothiazole compound shown as a formula I and medical application thereof, and especiallyrelates to application of the benzothiazole compound serving as a USP7C-terminal structural domain regulating agent in medicines for preventing and treating myelodysplastic syndromes and malignant tumors. The benzothiazole compound shown in the formula I or the pharmaceutically acceptable salt or solvate of the benzothiazole compound has strong binding force with USP7C-terminal protein; and the protein level of DNMT1 in tumor cells can be reduced, so that the compound can be applied to the preparation of USP7 regulators, has a remarkable anti-tumor cell proliferation effect, and can be used for preparing medicines for preventing or treating myelodysplastic syndrome and malignant tumors.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Novel benzothiazole derivatives with a broad antifungal spectrum: Design, synthesis and structure-activity relationships

N-Myristoyltransferase (NMT) is a new target for the development of novel antifungal agents. The benzothiazole derivative FR1335 is a highly potent NMT inhibitor with fungicidal activity. However, FTR1335 was only active against Candida albicans and its a

2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors

The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein the substituent is attached to the 5- or 6- position of the benzazole; Xindependently represents S, O, SO, SO2;Yindependently represents S, O, NR2, SO, SO2;Aindependently represents ←CO-, ←CS-, ←SO-, ←SO2-, ←CO2-, ←CONR8-, ←NR8CO-, ←NR8CONR9-, ←NR8COO-, ←NR8NR9CO-, ←NR8OCO-, ←ONR8CO-, ←NR8SO2-, where ← indicates the point of attachment to R3; and wherein R1 to R19 in formula (I) represent independently of each other a variety of different substituents comprising alkyl, aryl, aralkyl, alkylaryl, heteroaryl groups and monofunctional moieties. These compounds are useful as protein kinase inhibitors in the treatment of i.a. cancer.

Benzazole analogues and uses thereof

The present invention relates to N2-heteroaryl-benzazole-2,(5 or 6)-diamine derivatives and compositions thereof as protein kinase inhibitors for the treatment of e.g. cancer.

Synthesis and biological evaluation of benzothiazole derivatives as potent antitumor agents

Based on 2-methyl-4-nitro-2H-pyrazole-3-carboxylic acid[2- (cyclohexanecarbonylamino)benzothiazol-6-yl]amide (1), which shows selective cytotoxicity against tumorigenic cell lines, 2,6-dichloro-N-[2- (cyclopropanecarbonylamino)benzothiazol-6-yl]benzamide (13b) was designed and synthesized as a biologically stable derivative containing no nitro group. The highly potent derivative 13b exhibited excellent in vivo inhibitory effect on tumor growth.